A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Medical University of South Carolina, Charleston, South Carolina +2 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Recruiting
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: Digestive Disease Research Center, LLC, Greenwood, South Carolina
Conditions: NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
Recruiting
A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Prisma Health Gastroenterology and Liver Center, Greenville, South Carolina +1 locations
Conditions: Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes